Genomics & Pharmacogenomics

Biography

Biography: Lifshits G.I.

Abstract

Antithrombotic therapy is widely used to prevent thrombotic events. There are inter-individual differences of therapeutic effects and adverse drug reactions (such as bleeding or thrombosis due to the failure of the drug) observed in some patients. The efficacy and safety of antithrombotic drugs is enhanced by the timely control laboratory markers of hemostasis. The problem of antithrombotic therapy is an individual response to drugs depending on genetic factors (CYP2C9, CYP3A4, CYP2C19, and others), metabolic status, food, combination with other drugs. Therefore, individually calibrated doses of drugs should be prescribed based on its effectiveness to qualify for the "safe passage" between the risk of bleeding and the risk of thrombosis, which in both cases may lead to death or disability. These conditions led to the investigation aimed at developing a new device for multiparametric study of blood coagulation and platelet aggregation that allows patients to perform measurements at home using capillary blood. Thus the proposed equipment combines the functionality of two devices: to determine the international normalized ratio (INR) and platelet aggregation in response to ADP, and further to be able to transmit information to the physician using the Internet, as well as it should be portable and easy to use. Now we are testing the device in comparison with standard laboratory methods for measuring INR and platelet aggregation. In addition to the device, we have also developed instructions for personification of multiplicity and conditions of its use by patients depending on the individual genotype.